← Leaderboards
Isabel Kurth
Rgenix, Inc.
$1,838,914
Attributed
$1,838,914
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2014–17$2M$1.5M$1M$500K$0
'14
'15
'16
'17
Funding mix
By agency
NIH$1,838,914 · 2
By mechanism
R44$1,639,260 · 1
R43$199,654 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Outcome Forecast”
- Peter C Adamson · National Childhood Cancer Foundation$123,724,020
- Monica M Bertagnolli · Strang Cancer Prevention Center$50,120,149
- Norman Wolmark · Nsabp Foundation, Inc.$43,919,107
- Richard L Schilsky · University Of Chicago$40,064,700
- Walter John Curran · Thomas Jefferson University$35,876,624
- Ian M Thompson · University Of Texas Hlth Sci Ctr San Ant$27,122,576
Research focus
Outcome ForecastTumorIncidenceNeoplasm MetastasisProtocols DocumentationSmall Business Innovation Research GrantCohortImmunotherapyMeasurementMetastatic MelanomaPreventPrimary NeoplasmRecurrenceSamplingCancer CellAdjuvantDiagnosisImmunohistochemistryBiological MarkersLeadMelanomaMetastasis PreventionBiotechnologyApolipoprotein E
Grant awards (3)
Development of an LXR agonist as first in class therapy for treatment of metastatic melanoma$521,277
R44 · FY2017 · CA · contact PI
Development of an LXR agonist as first in class therapy for treatment of metastatic melanoma$1,117,983
R44 · FY2016 · CA · contact PI
A microRNA based prognostic service that predicts melanoma metastasis likelihood$199,654
R43 · FY2014 · CA · contact PI